- Conditions
- Malaria
- Interventions
- AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 687
matching trials from the live ClinicalTrials.gov search.
- Conditions
- SARS-CoV-2 Infection
- Interventions
- B/HPIV3/S-6P
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leishmaniasis, Cutaneous
- Interventions
- WR 279,396
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lyme Disease
- Interventions
- MicroB-plex Lyme Immunoassay
- Diagnostic Test
- Lead sponsor
- MicroB-plex, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- MVA-BN-Filo, Ad26. ZEBOV, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Yellow Fever
- Interventions
- Yellow Fever 17DD Vaccine
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 9 Months to 23 Months
- Enrollment
- 1,788 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Plasmodium Falciparum Malaria, Vaccines
- Interventions
- MSP1(42)-FVO & MSP1(42)-3D7
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- HIV Infections
- Interventions
- VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Malaria, Vivax
- Interventions
- Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Culver City, California • Baltimore, Maryland
- Conditions
- Huntington's Disease
- Interventions
- intra-striatal rAAV5-miHTT, Imitation (sham) surgery
- Genetic · Other
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 9 more
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Interventions
- Placebo, PIZV
- Drug · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
- Conditions
- Lyme Disease
- Interventions
- TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
- Conditions
- Sickle Cell Disease
- Interventions
- Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 13 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • Sacramento, California + 4 more
- Conditions
- Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome, Post-COVID-19 Condition, Postural Orthostatic Tachycardia Syndrome, Lyme Disease, Post-Treatment Lyme Disease Syndrome, Fibromyalgia, Cancer-Related Fatigue, Neuromuscular Diseases, Fatigue, POLG-Related Disorders
- Interventions
- Mito Map Energy Score and Home Functional Assessments
- Other
- Lead sponsor
- AI Agent Vault, Inc. d/b/a Precision Mito
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV, TBC-MVA and TBC-FPV
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more
- Conditions
- Healthy Volunteer
- Interventions
- Low Dose TP-05, High Dose TP-05, Placebo Comparator
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Marburg Virus Disease
- Interventions
- cAd3-Marburg vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Dengue
- Interventions
- Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Shigella Infection, Enterotoxigenic Escherichia Coli Infection
- Interventions
- strain CVD 1208S-122, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
- Conditions
- Dengue Fever
- Interventions
- rDEN2/4delta30(ME) vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Viral Infection
- Interventions
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Parotid Salivary Dysfunction
- Interventions
- Gene Transfer, AdhAQP1
- Genetic · Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland